Aaron J Katz1, Ronald C Chen2, Deborah S Usinger3, Susanne M Danus4, Leah L Zullig4,5. 1. Department of Population Health, University of Kansas Medical Center, Kansas City, KS, 66160, USA. akatz3@kumc.edu. 2. Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, USA. 3. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. Center of Innovation to Accelerate Discovery and Practice Transformation, Durham Veterans Affairs Health Care System, Durham, NC, USA. 5. Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Abstract
PURPOSE: Cardiovascular disease (CVD) is a common cause of mortality among men with prostate cancer. However, receipt of preventive care and management of pre-existent CVD has not been well studied in prostate cancer survivors. METHODS: This study examined a prospective cohort of men newly diagnosed with localized prostate cancer between 2011 and 2013 throughout North Carolina linked to Medicare and private insurance claims and clinical data from the Veterans Affairs (VA). In patients without pre-existent CVD, the primary outcome was a composite measure of annual preventive care (blood glucose screening, cholesterol level testing, and ≥ 1 primary care provider visit). In patients with pre-existent CVD, the primary outcome was annual cardiologist visit; blood glucose, cholesterol level testing, and primary care visits were also assessed. RESULTS: Our sample comprised 492 patients successfully linked to insurance claims and/or VA data, among whom 103 (20.9%) had pre-existent CVD. Receipt of preventive care declined from 52.7% (95% confidence interval [CI], 47.7 to 57.6%) during the first year after prostate cancer diagnosis to 40.8% (95% CI: 33.7 to 48.4%) during the third year. Among patients with pre-existent CVD, only 23.4% (95% CI: 13.6 to 37.2%) visited a cardiologist in all 3 years. Black men were more likely than White men to visit a cardiologist the first year (risk ratio [RR] = 1.72, 95% CI: 1.10 to 2.71). CONCLUSION: In a population-based cohort of prostate cancer survivors, receipt of CVD preventive care declined over time, and frequency of cardiologist-led management of pre-existent CVD was low. IMPLICATIONS FOR CANCER SURVIVORS: There is a need to improve clinical strategies for reducing cardiovascular risk and managing pre-existent CVD in prostate cancer survivors.
PURPOSE: Cardiovascular disease (CVD) is a common cause of mortality among men with prostate cancer. However, receipt of preventive care and management of pre-existent CVD has not been well studied in prostate cancer survivors. METHODS: This study examined a prospective cohort of men newly diagnosed with localized prostate cancer between 2011 and 2013 throughout North Carolina linked to Medicare and private insurance claims and clinical data from the Veterans Affairs (VA). In patients without pre-existent CVD, the primary outcome was a composite measure of annual preventive care (blood glucose screening, cholesterol level testing, and ≥ 1 primary care provider visit). In patients with pre-existent CVD, the primary outcome was annual cardiologist visit; blood glucose, cholesterol level testing, and primary care visits were also assessed. RESULTS: Our sample comprised 492 patients successfully linked to insurance claims and/or VA data, among whom 103 (20.9%) had pre-existent CVD. Receipt of preventive care declined from 52.7% (95% confidence interval [CI], 47.7 to 57.6%) during the first year after prostate cancer diagnosis to 40.8% (95% CI: 33.7 to 48.4%) during the third year. Among patients with pre-existent CVD, only 23.4% (95% CI: 13.6 to 37.2%) visited a cardiologist in all 3 years. Black men were more likely than White men to visit a cardiologist the first year (risk ratio [RR] = 1.72, 95% CI: 1.10 to 2.71). CONCLUSION: In a population-based cohort of prostate cancer survivors, receipt of CVD preventive care declined over time, and frequency of cardiologist-led management of pre-existent CVD was low. IMPLICATIONS FOR CANCER SURVIVORS: There is a need to improve clinical strategies for reducing cardiovascular risk and managing pre-existent CVD in prostate cancer survivors.
Authors: Ronald C Chen; William R Carpenter; Mimi Kim; Laura H Hendrix; Robert P Agans; Anne-Marie Meyer; Anna Hoffmeyer; Bryce B Reeve; Matthew E Nielsen; Deborah S Usinger; Tara S Strigo; Anne M Jackman; Mary Anderson; Paul A Godley Journal: J Comp Eff Res Date: 2015-01 Impact factor: 1.744
Authors: Jordan A Holmes; Roger F Anderson; Leroy G Hoffman; Timothy N Showalter; Mohit Kasibhatla; Sean P Collins; Michael A Papagikos; Brittany D Barbosa; Kristy Alligood; Lori J Stravers; Zahra Mahbooba; Andrew Z Wang; Ronald C Chen Journal: Int J Radiat Oncol Biol Phys Date: 2018-08-09 Impact factor: 7.038
Authors: Kimberly D Miller; Leticia Nogueira; Angela B Mariotto; Julia H Rowland; K Robin Yabroff; Catherine M Alfano; Ahmedin Jemal; Joan L Kramer; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2019-06-11 Impact factor: 508.702
Authors: Anne-Marie Meyer; Andrew F Olshan; Laura Green; Adrian Meyer; Stephanie B Wheeler; Ethan Basch; William R Carpenter Journal: N C Med J Date: 2014 Jul-Aug
Authors: Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry; Karina W Davidson; John W Epling; Francisco A R García; Matthew W Gillman; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Michael L LeFevre; Carol M Mangione; William R Phillips; Douglas K Owens; Maureen G Phipps; Michael P Pignone Journal: JAMA Date: 2016-11-15 Impact factor: 56.272
Authors: Saro H Armenian; Christina Lacchetti; Ana Barac; Joseph Carver; Louis S Constine; Neelima Denduluri; Susan Dent; Pamela S Douglas; Jean-Bernard Durand; Michael Ewer; Carol Fabian; Melissa Hudson; Mariell Jessup; Lee W Jones; Bonnie Ky; Erica L Mayer; Javid Moslehi; Kevin Oeffinger; Katharine Ray; Kathryn Ruddy; Daniel Lenihan Journal: J Clin Oncol Date: 2016-12-05 Impact factor: 44.544
Authors: Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian Journal: Circulation Date: 2019-03-17 Impact factor: 29.690
Authors: Ronald C Chen; Ramsankar Basak; Anne-Marie Meyer; Tzy-Mey Kuo; William R Carpenter; Robert P Agans; James R Broughman; Bryce B Reeve; Matthew E Nielsen; Deborah S Usinger; Kiayni C Spearman; Sarah Walden; Dianne Kaleel; Mary Anderson; Til Stürmer; Paul A Godley Journal: JAMA Date: 2017-03-21 Impact factor: 56.272
Authors: Lova Sun; Ravi B Parikh; Rebecca A Hubbard; John Cashy; Samuel U Takvorian; David J Vaughn; Kyle W Robinson; Vivek Narayan; Bonnie Ky Journal: JAMA Netw Open Date: 2021-02-01